| Document |
Document Title |
|
WO/2023/051701A1 |
An mRNA against SARS-CoV-2 infection. The template DNA of the mRNA comprises an antigen encoding region. The antigen encoding region encodes a signal peptide-free S protein of a SARS-CoV-2 Delta mutant, wherein the S protein of the Delta...
|
|
WO/2023/051462A1 |
The present invention relates to a fusion polypeptide of GLP-1 analog. Specifically, the present invention relates to a fusion polypeptide of GLP-1 analog or a pharmaceutically acceptable salt thereof, wherein the fusion polypeptide of G...
|
|
WO/2023/051850A1 |
Disclosed are a recombinant fusion protein derived from an HR region of an S2 protein of SARS-CoV-2 and an application of the recombinant fusion protein. The SARS-CoV-2 recombinant fusion protein is a recombinant fusion protein obtained ...
|
|
WO/2023/051660A1 |
Provided are a drug for treating Sjogren's syndrome using a TACI-Fc fusion protein, and a dosage regimen, a dosing interval and an administration mode thereof. The results show that the provided TACI-Fc fusion protein significantly impro...
|
|
WO/2023/044774A1 |
Provided are recombinant peptides comprising a recombinant human p75 TNF receptor and TPO mimetic peptides linked by an Fc fragment of IgG1. The recombinant peptides can form a homodimer by inter-chain disulfide bond in the Fc region and...
|
|
WO/2023/046110A1 |
Provided is an engineered immune cell co-expressing CCR2b, wherein the engineered immune cell is a T cell or an NK cell. NKG2D extracellular domain-containing CAR molecules and CCR2b are co-expressed in a CAR-T cell, so that the sensitiv...
|
|
WO/2023/048290A1 |
This method for producing a polypeptide comprising expressing a polypeptide as a tag-added polypeptide comprises expressing the tag-added polypeptide from a nucleic acid having: a base sequence which is arranged immediately after a start...
|
|
WO/2023/049926A2 |
Provided herein are fusion polypeptides comprising a Cpfl domain lacking nuclease activity and an endonuclease domain. Also provided herein are fusion polypeptides further comprising a genomic modification domain, which in some embodimen...
|
|
WO/2023/045470A1 |
The present invention provides a recombinant thyroid stimulating hormone receptor protein, a preparation method therefor and an application thereof. The recombinant thyroid stimulating hormone receptor protein comprises a TSHR protein ex...
|
|
WO/2023/049774A1 |
Described herein is a generalizable strategy to rapidly and irreversibly activate protein function with full spatiotemporal control. Through development of an exogenously triggerable self-assembling protein construct, bioactive proteins ...
|
|
WO/2023/044991A1 |
Provided is a chimeric antigen receptor specifically targeting a tumor EpCAM antigen, comprising an extracellular antigen recognition domain, a transmembrane domain and an intracellular signaling domain, the extracellular antigen recogni...
|
|
WO/2023/046116A1 |
The present invention relates to the field of biomedicine, and in particular to a polypeptide complex of interleukin 15 and a receptor thereof, and a use thereof. A non-natural interchain bond is present between IL15 and IL15Rα in the p...
|
|
WO/2023/046047A1 |
Provided are a heterodimeric protein and an application thereof. The heterodimeric protein contains: (1) a light chain and a heavy chain 1, which are compounded to form a target part expressing binding specificity for a tumor antigen or ...
|
|
WO/2023/047129A1 |
The invention relates to fusion polypeptides, and to immunogenic polypeptides and their use as vaccines for treating, preventing or ameliorating a wide range of infectious diseases, for example caused by a virus, bacterium or fungus, or ...
|
|
WO/2023/045997A1 |
Provided are an anti-Claudin18.2 antibody or an antigen binding fragment thereof and a use thereof. Further provided are a bispecific antibody, a multispecific antibody, a multi-functional fusion protein and a composition thereof contain...
|
|
WO/2023/046156A1 |
Provided are IL-2 variants and polypeptide complexes comprising the IL-2 variants, the methods of producing the same and the uses thereof. The IL-2 variants and fusion proteins can be used as a potent agent for the treatment of cancers, ...
|
|
WO/2023/048151A1 |
The present invention provides a compound having a corona virus proliferation inhibition activity, and/or a pharmaceutical composition containing the compound having a corona virus proliferation inhibition activity. A compound represente...
|
|
WO/2023/045361A1 |
Provided are a fusion protein of an anti-TIGIT antibody and IL2 or a variant thereof, and an application thereof. Specifically, a fusion protein is provided, which comprises: (a) a first polypeptide comprising an anti-TIGIT antibody or a...
|
|
WO/2023/045001A1 |
A modified SIS membrane for tissue repair, a preparation method therefor and a use thereof. Specifically provided is a composition comprising a fusion polypeptide-modified SIS film and an extracellular vesicle, as well as a preparation m...
|
|
WO/2023/044457A1 |
The present disclosure generally relates to, inter alia, a class of chimeric switch receptors containing an endodomain of an IL-9 receptor, engineered to modulate transcriptional regulation in a ligand-dependent manner. The disclosure al...
|
|
WO/2023/040667A1 |
Provided is a recombinant fusion protein, comprising a PD-L1 antibody or antibody fragment thereof. At least one paratope of the PD-L1 antibody or antibody fragment thereof is connected to an extracellular Ig-like domain of a signal regu...
|
|
WO/2023/044318A2 |
The present invention is related to, inter alia, de novo IL-2Rβ binding polypeptides.
|
|
WO/2023/044348A1 |
The present invention provides methods of treating pulmonary disorders with modulators of the Wnt signaling pathway. Also provided are methods of related methods of dosing and pharmaceutical compositions.
|
|
WO/2023/044290A1 |
Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2023/044461A2 |
The present disclosure generally relates to, inter alia, a class of chimeric switch receptors containing an endodomain of an IL-9 receptor, engineered to modulate transcriptional regulation in a ligand-dependent manner. The disclosure al...
|
|
WO/2023/040963A1 |
The present disclosure provides a novel polypeptide. Also provided is an ophthalmic composition for treating or preventing dry eye (DE) or DE associated disorders. Also provided is a method for treating or preventing DE or DE associated ...
|
|
WO/2023/044321A1 |
The present invention discloses proteolytically cleavable peptide (CP) substrates, polypeptides, polypeptide constructs and prodrug constructs comprising the proteolytically cleavable peptides (e.g., cytokine prodrugs), and methods of us...
|
|
WO/2023/039667A1 |
The present disclosure describes multivalent (e.g., decavalent or dodecavalent) polypeptide constructs capable of binding to one or more viral spike protein(s) and capable of intercepting the interaction of a spike protein of a viral par...
|
|
WO/2023/040205A1 |
Provided are a fusion protein and a protein combination thereof, the fusion protein comprising nicotinamide riboside kinase (NRK) and ATP cyclase linked to each other using a linker, and the protein combination comprising the NRK and the...
|
|
WO/2023/043473A1 |
A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human TGF-β. In certain aspects, the disclosed invention is based, on engineering of a heterodimer...
|
|
WO/2023/036191A1 |
A vaccine for a novel coronavirus SARS-CoV-2 Delta variant and an application, the vaccine comprising a fusion protein, and the fusion protein comprising: (1) an interferon or a functional fragment thereof; (2) a novel coronavirus SARS-C...
|
|
WO/2023/036043A1 |
Provided are an anti-cancer binding molecule and the use thereof, and specifically provided is a bispecific binding molecule of 4-1BB and GPC3. The bispecific binding molecule comprises a first domain that specifically binds to 4-1BB, an...
|
|
WO/2023/036270A1 |
Disclosed is an antigen-targeting, anti-CD16A and immune effector cell-activating trifunctional fusion protein, which comprises a CD16A binding region that specifically binds to CD16A, a TAA binding region that specifically binds to a tu...
|
|
WO/2023/035083A1 |
Optimized self-assembled polypeptide complexes comprising 1) fusion polypeptides comprising Fc polypeptides linked to nanocage monomers or subunits thereof and 2) fusion polypeptides comprising an antigen-binding antibody fragment.
|
|
WO/2023/038020A1 |
The present invention addresses the problem of providing: a composition for modifying a nucleic acid sequence, which is not dependent on a PAM sequence or a PFS sequence; and a method for modifying a target site of a nucleic acid sequenc...
|
|
WO/2023/035056A1 |
In aspects, a self-assembled polypeptide complex comprises (a) a plurality of first fusion polypeptides, each first fusion polypeptide comprising (1) an Fc polypeptide linked to (2) a nanocage monomer or subunit thereof, wherein the Fc p...
|
|
WO/2023/033025A1 |
A plasmid transfection agent that comprises a peptide containing an amino acid sequence represented by SEQ ID NO: 1. SEQ ID NO: 1: CXDXXXXYXC (wherein: X represents an arbitrary amino acid residue; C represents cysteine; D represents a...
|
|
WO/2023/029089A1 |
Provided is a novel anti-CD3 humanized antibody. The anti-CD3 humanized antibody can specifically bind to human and monkey CD3 proteins, and said antibody has good biological activity.
|
|
WO/2023/033129A1 |
In the present invention, by linking dolastatin 10 or a derivative thereof to an antibody or fragment thereof having immunological reactivity with CAPRIN-1 protein having an amino acid sequence shown in any one of the even numbered SEQ I...
|
|
WO/2023/029532A1 |
Provided are engineered Cas6 proteins with decreased ability to process DR sequences of guide RNAs and uses thereof.
|
|
WO/2023/030340A1 |
Provided is a novel design of guide RNA and uses thereof. In one aspect, the guide RNA comprises a spacer sequence flanked by a direct repeat sequence at both the 5' end and the 3' end of the spacer sequence.
|
|
WO/2023/030511A1 |
Provided is a bi-functional fusion protein that targets both TGFβ ligands and AREG, and blocks TGFβand AREG signaling simultaneously, as well as a nucleic acid molecule encoding the bi-functional fusion protein, an expression vector fo...
|
|
WO/2023/028715A1 |
A polypeptide comprising one or more variant Fc regions, each of the variant Fc regions comprising two CH2 domains, wherein at least one of the CH2 domains in at least one of the variant Fc regions is a variant CH2 domain, and wherein am...
|
|
WO/2023/030539A1 |
Provided herein are antibodies and antigen-binding fragment thereof targeting GPC3, and chimeric antigen receptors having one or more anti-GPC3 antigen-binding fragments thereof. Further provided are engineered immune effector cells (e.g...
|
|
WO/2023/030433A1 |
A bispecific antibody specifically binding to ALK-1 and VEGF, a pharmaceutical composition comprising the antibody, and the use thereof. The bispecific antibody against ALK-1 and VEGF comprises a first antigen binding region (ALK-1 bindi...
|
|
WO/2023/033124A1 |
Provided is a polynucleotide from which a cell or extracellular vesicle capable of satisfactorily activating antigen-specific T cells can be produced. Provided is a polynucleotide containing at least one sequence selected from the grou...
|
|
WO/2023/030408A1 |
Provided are a TGFβRII mutant fragment and an application thereof. The TGFβRII mutant fragment comprises at most 122 amino acids of a C-terminal of a TGFβRII extracellular domain, a flexible fragment, and an N-terminal fragment of the...
|
|
WO/2023/034742A1 |
The present disclosure relates generally to compositions and methods for robustly improving fitness and function of CAR T cells. More particularly, the present disclosure relates to novel chimeric polypeptides capable of anchoring adenos...
|
|
WO/2023/034515A2 |
Provided herein are oligonucleotides, cell-penetrating peptides, and peptide- oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need the...
|
|
WO/2023/034810A1 |
Disclosed herein are fusion peptides comprising a fluorescent domain and a rare earth element detection domain capable of binding to a rare earth element and fluorescing when exposed to light when a rare earth element is bound and compos...
|
